OPK – OPKO Health, Inc.
OPK — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.48
Margin Of Safety %
Put/Call OI Ratio
0.06
EPS Next Q Diff
-0.03
EPS Last/This Y
-0.04
EPS This/Next Y
0.01
Price
1.18
Target Price
3.4
Analyst Recom
1.57
Performance Q
-8.59
Upside
-664.1%
Beta
1.53
Ticker: OPK
19 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | OPK | 1.215 | 0.05 | 0.00 | 30031 |
| 2026-03-10 | OPK | 1.185 | 0.05 | 0.03 | 30192 |
| 2026-03-11 | OPK | 1.16 | 0.05 | 0.00 | 30050 |
| 2026-03-12 | OPK | 1.165 | 0.05 | 0.00 | 30119 |
| 2026-03-13 | OPK | 1.16 | 0.05 | 0.00 | 30119 |
| 2026-03-17 | OPK | 1.195 | 0.05 | 0.38 | 30105 |
| 2026-03-18 | OPK | 1.175 | 0.05 | 0.10 | 30134 |
| 2026-03-19 | OPK | 1.165 | 0.05 | 0.04 | 29775 |
| 2026-03-20 | OPK | 1.115 | 0.05 | 0.30 | 29763 |
| 2026-03-23 | OPK | 1.145 | 0.05 | 0.07 | 25508 |
| 2026-03-24 | OPK | 1.135 | 0.06 | 0.06 | 26232 |
| 2026-03-25 | OPK | 1.2 | 0.06 | 0.00 | 26443 |
| 2026-03-26 | OPK | 1.16 | 0.06 | 0.15 | 26884 |
| 2026-03-27 | OPK | 1.125 | 0.06 | 0.11 | 26795 |
| 2026-03-30 | OPK | 1.105 | 0.06 | 0.00 | 26807 |
| 2026-03-31 | OPK | 1.145 | 0.06 | 0.00 | 26892 |
| 2026-04-01 | OPK | 1.135 | 0.06 | 0.00 | 27077 |
| 2026-04-02 | OPK | 1.145 | 0.06 | 0.00 | 27313 |
| 2026-04-06 | OPK | 1.19 | 0.06 | 0.00 | 27289 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
19 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | OPK | 1.21 | - | - | -0.34 |
| 2026-03-10 | OPK | 1.18 | - | - | -0.34 |
| 2026-03-11 | OPK | 1.16 | - | - | -0.34 |
| 2026-03-12 | OPK | 1.16 | - | - | -0.34 |
| 2026-03-13 | OPK | 1.19 | - | - | -0.34 |
| 2026-03-17 | OPK | 1.20 | - | - | -0.34 |
| 2026-03-18 | OPK | 1.17 | - | - | -0.34 |
| 2026-03-19 | OPK | 1.16 | - | - | -0.34 |
| 2026-03-20 | OPK | 1.12 | - | - | -0.34 |
| 2026-03-23 | OPK | 1.14 | - | - | -0.34 |
| 2026-03-24 | OPK | 1.14 | - | - | -0.34 |
| 2026-03-25 | OPK | 1.20 | - | - | -0.34 |
| 2026-03-26 | OPK | 1.16 | - | - | -0.34 |
| 2026-03-27 | OPK | 1.12 | - | - | -0.34 |
| 2026-03-30 | OPK | 1.11 | - | - | -0.34 |
| 2026-03-31 | OPK | 1.15 | - | - | -0.34 |
| 2026-04-01 | OPK | 1.13 | - | - | -0.34 |
| 2026-04-02 | OPK | 1.14 | - | - | -0.34 |
| 2026-04-06 | OPK | 1.19 | - | - | -0.34 |
| 2026-04-07 | OPK | 1.18 | - | - | -0.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | OPK | 0.65 | 1.18 | 8.19 |
| 2026-03-10 | OPK | 0.65 | 1.18 | 8.19 |
| 2026-03-11 | OPK | 0.65 | 1.18 | 8.11 |
| 2026-03-12 | OPK | 0.65 | 1.18 | 8.11 |
| 2026-03-13 | OPK | 0.65 | 1.18 | 8.11 |
| 2026-03-17 | OPK | 0.65 | 1.19 | 8.11 |
| 2026-03-18 | OPK | 0.65 | 1.19 | 8.11 |
| 2026-03-19 | OPK | 0.65 | 1.19 | 8.11 |
| 2026-03-20 | OPK | 0.66 | 1.19 | 8.11 |
| 2026-03-23 | OPK | 0.66 | 1.20 | 8.11 |
| 2026-03-24 | OPK | 0.66 | 1.20 | 8.11 |
| 2026-03-25 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-03-26 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-03-27 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-03-30 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-03-31 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-04-01 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-04-02 | OPK | 0.66 | 1.20 | 8.48 |
| 2026-04-06 | OPK | 0.66 | 1.19 | 8.48 |
| 2026-04-07 | OPK | 0.66 | 1.19 | 8.48 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.07
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
0.66
Institutional Transactions
1.19
Beta
1.53
Average Sales Estimate Current Quarter
130
Average Sales Estimate Next Quarter
135
Fair Value
Quality Score
45
Growth Score
30
Sentiment Score
72
Actual DrawDown %
77.5
Max Drawdown 5-Year %
-83.2
Target Price
3.4
P/E
Forward P/E
PEG
P/S
1.46
P/B
0.7
P/Free Cash Flow
EPS
-0.3
Average EPS Est. Cur. Y
-0.34
EPS Next Y. (Est.)
-0.33
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-37.19
Relative Volume
0.7
Return on Equity vs Sector %
-45.3
Return on Equity vs Industry %
-28.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
◆
OPK
Healthcare
$1.17
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
2/20
Pullback
13/25
Volume
6/15
Valuation
12/20
TP/AR
1/10
Options
0/10
RSI
50.2
Range 1M
68%
Sup Dist
2.6%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
1/25
Growth
11/30
Estimates
1/20
Inst/Vol
3/15
Options
0/10
EPS Yr
7.1%
EPS NY
10.3%
52W%
16.8%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+190.6% upside
Quality
4/30
Valuation
16/30
Growth
6/25
Stability
6/10
LT Trend
1/5
Upside
+190.6%
Quality
45
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2275
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
OPK
Latest News
—
Caricamento notizie per OPK…
stock quote shares OPK – OPKO Health, Inc. Stock Price stock today
news today OPK – OPKO Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OPK – OPKO Health, Inc. yahoo finance google finance
stock history OPK – OPKO Health, Inc. invest stock market
stock prices OPK premarket after hours
ticker OPK fair value insiders trading